Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (OTCPK:AZNCF)

Immunology and Exosome Cancer Drug Investors Pay Attention to AstraZeneca Acquisition

Accesswire October 1, 2013

Misys Transforms its Business Using SumTotal's Talent Expansion Solutions

Business Wire September 26, 2013

New Hypoglycemia and Pancreatitis Subanalyses from the Onglyza® (saxagliptin) SAVOR Cardiovascular Outcomes Trial Presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Business Wire September 26, 2013

New Phase III Data Showed Dapagliflozin Significantly Reduced HbA1c Compared to Placebo at 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with the Combination of Metformin Plus Sulfonylurea

Business Wire September 24, 2013

Technical Scrutiny: GlaxoSmithKline PLC, Keryx Biopharma Inc., AstraZeneca PLC, and Raptor Pharma Corp.

PR Newswire September 19, 2013

SumTotal Extends elixHR Platform with SnapLogic Cloud Integration

Business Wire September 17, 2013

Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial

Business Wire September 2, 2013

New Antibiotic Treatment for Patients With Serious Skin Infections Becomes Available in Wales

PR Newswire August 1, 2013

New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor)

Business Wire July 31, 2013

U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes

Business Wire July 25, 2013

SumTotal Named IHRIM 2013 Partner of the Year

Business Wire July 24, 2013

AstraZeneca Takes a More Personal Approach to Connecting with NEXIUM® (esomeprazole magnesium) Patients

PR Newswire July 15, 2013

Trial Results, New Facilities, Approved Labels, Spinoffs, and M&As Support Long-Term Growth Strategies - Research Report on Pfizer, Johnson & Johnson, Merck, Zoetis, and AstraZeneca

PR Newswire July 4, 2013

AtheroNova's AHRO-001 Targets Much More than Cholesterol, Shows New UCLA Study

Accesswire July 2, 2013

Breakthrough Therapy Designation Status, Top-Line Results, and Business Proposals Boost Long-Term Growth in Pharmaceutical Companies - Research Report on Novartis, AstraZeneca, GSK, Sanofi, and Rigel

PR Newswire June 26, 2013

Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin after 14 Days as Add-on to Insulin in Adult Patients with Type 1 Diabetes Presented at the 2013 American Diabetes Association Scientific Sessions®

Business Wire June 22, 2013

AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza® (saxagliptin)

Business Wire June 19, 2013

Getting Healthy with Acquisitions, New Products, and Favorable Court Rulings - Research Report on AstraZeneca, Herbalife, CardioNet, Cyberonics, and NuVasive

PR Newswire June 17, 2013

AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®

Business Wire June 14, 2013

AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based Therapies

Business Wire June 12, 2013